RANI vs. HOWL

Last updated Apr 1, 2026

Compare and contrast key facts about Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL).

Performance

RANI vs. HOWL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL). The values are adjusted to include any dividend payments, if applicable.

RANI vs. HOWL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RANI Rani Therapeutics Holdings, Inc.	-45.57%	-1.46%	-58.73%	-43.73%	-63.91%	48.64%
HOWL Werewolf Therapeutics, Inc.	31.43%	-57.20%	-61.66%	88.29%	-82.79%	-31.63%

Fundamentals

Market Cap RANI : $108.08M HOWL : $38.97M
EPS RANI : -$0.40 HOWL : -$1.33
PB Ratio RANI : 3.27 HOWL : 1.57
Total Revenue (TTM) RANI : $172.00K HOWL : $0.00
Gross Profit (TTM) RANI : -$51.00K HOWL : -$832.00K
EBITDA (TTM) RANI : -$37.15M HOWL : -$48.00M

Returns By Period

In the year-to-date period, RANI achieves a -45.57% return, which is significantly lower than HOWL's 31.43% return.

RANI

• 1D: -3.71%
• 1M: -46.36%
• YTD: -45.57%
• 6M: 47.02%
• 1Y: -41.68%
• 3Y*: -47.78%
• 5Y*: —
• 10Y*: —

HOWL

• 1D: 4.48%
• 1M: 38.72%
• YTD: 31.43%
• 6M: -57.74%
• 1Y: -14.36%
• 3Y*: -31.58%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RANI vs. HOWL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RANI

RANI Risk / Return Rank: 45
RANI Sharpe Ratio Rank: 34
RANI Sortino Ratio Rank: 73
RANI Omega Ratio Rank: 71
RANI Calmar Ratio Rank: 20
RANI Martin Ratio Rank: 26

HOWL

HOWL Risk / Return Rank: 37
HOWL Sharpe Ratio Rank: 34
HOWL Sortino Ratio Rank: 44
HOWL Omega Ratio Rank: 42
HOWL Calmar Ratio Rank: 33
HOWL Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RANI vs. HOWL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RANI	HOWL	Difference
Sharpe ratio Return per unit of total volatility	-0.15	-0.14	-0.01
Sortino ratio Return per unit of downside risk	1.75	0.55	+1.20
Omega ratio Gain probability vs. loss probability	1.22	1.07	+0.15
Calmar ratio Return relative to maximum drawdown	-0.62	-0.26	-0.36
Martin ratio Return relative to average drawdown	-0.87	-0.45	-0.42
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RANI vs. HOWL - Sharpe Ratio Comparison

The current RANI Sharpe Ratio is -0.15, which is comparable to the HOWL Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of RANI and HOWL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RANI	HOWL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.15	-0.14	-0.01
Sharpe Ratio (All Time) Calculated using the full available price history	-0.28	-0.44	+0.16

Correlation

The correlation between RANI and HOWL is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RANI vs. HOWL - Dividend Comparison

Neither RANI nor HOWL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RANI vs. HOWL - Drawdown Comparison

The maximum RANI drawdown since its inception was -98.83%, roughly equal to the maximum HOWL drawdown of -97.30%. Use the drawdown chart below to compare losses from any high point for RANI and HOWL.

Drawdown Indicators

	RANI	HOWL	Difference
Max Drawdown Largest peak-to-trough decline	-98.83%	-97.30%	-1.53%
Max Drawdown (1Y) Largest decline over 1 year	-74.22%	-74.92%	+0.70%
Current Drawdown Current decline from peak	-97.90%	-95.90%	-2.00%
Average Drawdown Average peak-to-trough decline	-79.90%	-76.14%	-3.76%
Ulcer Index Depth and duration of drawdowns from previous peaks	52.90%	42.68%	+10.22%

Volatility

RANI vs. HOWL - Volatility Comparison

Rani Therapeutics Holdings, Inc. (RANI) has a higher volatility of 33.24% compared to Werewolf Therapeutics, Inc. (HOWL) at 28.40%. This indicates that RANI's price experiences larger fluctuations and is considered to be riskier than HOWL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RANI	HOWL	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.24%	28.40%	+4.84%
Volatility (6M) Calculated over the trailing 6-month period	153.01%	78.82%	+74.19%
Volatility (1Y) Calculated over the trailing 1-year period	277.14%	102.03%	+175.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	157.68%	102.55%	+55.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	157.68%	102.55%	+55.13%

Financials